The Integrative Studies on the Functional A-to-I RNA Editing Events in Human Cancers

Genomics Proteomics Bioinformatics. 2023 Jun;21(3):619-631. doi: 10.1016/j.gpb.2022.12.010. Epub 2023 Jan 25.

Abstract

Adenosine-to-inosine (A-to-I) RNA editing, constituting nearly 90% of all RNA editing events in humans, has been reported to contribute to the tumorigenesis in diverse cancers. However, the comprehensive map for functional A-to-I RNA editing events in cancers is still insufficient. To fill this gap, we systematically and intensively analyzed multiple tumorigenic mechanisms of A-to-I RNA editing events in samples across 33 cancer types from The Cancer Genome Atlas. For individual candidate among ∼ 1,500,000 quantified RNA editing events, we performed diverse types of downstream functional annotations. Finally, we identified 24,236 potentially functional A-to-I RNA editing events, including the cases in APOL1, IGFBP3, GRIA2, BLCAP, and miR-589-3p. These events might play crucial roles in the scenarios of tumorigenesis, due to their tumor-related editing frequencies or probable effects on altered expression profiles, protein functions, splicing patterns, and microRNA regulations of tumor genes. Our functional A-to-I RNA editing events (https://ccsm.uth.edu/CAeditome/) will help better understand the cancer pathology from the A-to-I RNA editing aspect.

Keywords: A-to-I RNA editing; Alternative splicing; Cancer; MicroRNA regulation; Protein recoding.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apolipoprotein L1 / genetics
  • Apolipoprotein L1 / metabolism
  • Carcinogenesis / genetics
  • Humans
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Neoplasms* / genetics
  • Neoplasms* / pathology
  • RNA Editing

Substances

  • MicroRNAs
  • APOL1 protein, human
  • Apolipoprotein L1
  • MIRN589 microRNA, human